Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).

Loma Linda University (LLU)

Status and phase

Enrolling

Phase 4

Conditions

Blunt Cerebrovascular Injury

Treatments

Drug: Aspirin 325Mg Tab, Aspirin 81Mg Tab

Study type

Interventional

Funder types

Other

Identifiers

NCT05868525

5220429

Details and patient eligibility

About

The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury.

The main questions it aims to answer are:

If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg.
If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.

Enrollment

98 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥18
All patients with blunt cerebrovascular injury are diagnosed by computed tomography angiography (CTA) upon admission

Exclusion criteria

Age <18
Pregnant women
No enteral route access for Aspirin administration
Patients who are on Heparin drip or other full dose anticoagulation when BCVI diagnosed
Patients who are on other Anti-Platelets aside from Aspirin when BCVI diagnosed
Patients with BCVI grade 5 injury based on Biffl classification
Presence of any contraindication or history of allergy to Aspirin
Patient with the diagnosis of acute stroke at the time of BCVI diagnosis matching the injured vessel territory on imaging
Patients with acute spinal trauma that needs surgical intervention